Dysmenorrhea is one of the most common problems affecting majority of females of reproductive age group. It substantially compromises the overall quality of life of the sufferer almost like a chronic illness. This study was aimed to evaluate the safety and efficacy of Spasmodart Tablet for the complaints of primary dysmenorrhea. A validated survey questionnaire was administered to General Practitioners, Obstetricians, Gynecologists, and General Surgeons. Safety and efficacy data were recorded based on their practice experience. Around 80% of study participants reported no side-effects among patients with Spasmodart and 20% of participants reported mild side-effects of gastric acidity and dizziness (15.1%), acidity, giddiness and nausea (11.3%). More than 60% of participants opined that 1-day dosage was sufficient to get results with Spasmodart in patients with primary dysmenorrhea and more than 30% rated the pain relief score as 8 followed by 7 (15.9%) and 10 (14.3%) (10 being highest/best and 1 being least). Around 85% of study participants responded that their patients felt much better than before with Spasmodart. Around one-fourth of the study participants rated score-8 for the safety of Spasmodart followed by 20.2% participants who rated score-10 score, 18.7% participants rated score-7, 16.3% participants rated score-9. With these results, we conclude that Spasmodart shows promising safety and efficacy in patients presented with primary dysmenorrhea.